Neoantigen Peptide Vaccine Plus Checkpoint Immunotherapy: Cancer Case Report
Case report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy produced anti-tumor response, demonstrating personalized combination immunotherapy.
Quick Facts
What This Study Found
Case report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy produced anti-tumor response, demonstrating personalized combination immunotherapy.
Key Numbers
Single pediatric patient with metastatic HCC achieved tumor regression and long-term remission with combined peptide vaccine and checkpoint immunotherapy.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Case report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.
- Published In:
- Frontiers in immunology, 16, 1674663 (2025)
- Authors:
- Amorelli, Germano, Rabsteyn, Armin(2), Maier, Claus-Philipp, Trautner, Finn, Holzer, Ursula, Schäfer, Jürgen Frank, Ebinger, Martin, Handgretinger, Rupert, Nahnsen, Sven, Rammensee, Hans-Georg, Lang, Peter
- Database ID:
- RPEP-09932
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Case report of neoantigen-targeting peptide vaccine combined with checkpoint inhibitor immunotherapy produced anti-tumor response, demonstrating personalized combination immunotherapy.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09932APA
Amorelli, Germano; Rabsteyn, Armin; Maier, Claus-Philipp; Trautner, Finn; Holzer, Ursula; Schäfer, Jürgen Frank; Ebinger, Martin; Handgretinger, Rupert; Nahnsen, Sven; Rammensee, Hans-Georg; Lang, Peter. (2025). Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.. Frontiers in immunology, 16, 1674663. https://doi.org/10.3389/fimmu.2025.1674663
MLA
Amorelli, Germano, et al. "Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.." Frontiers in immunology, 2025. https://doi.org/10.3389/fimmu.2025.1674663
RethinkPeptides
RethinkPeptides Research Database. "Case Report: A neoantigen-targeting peptide vaccine combined..." RPEP-09932. Retrieved from https://rethinkpeptides.com/research/amorelli-2025-case-report-a-neoantigentargeting
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.